Ledipasvir (formerly GS-5885), Treatment of chronic Hepatitis C infection
November 28, 2012. N12/139. STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL. USAN ZZ-132. LEDIPASVIR.
MOLECULAR FORMULA C49H54F2N8O6
MOLECULAR WEIGHT 889
CODE DESIGNATION GS-5885
CAS REGISTRY NUMBER 1256388-51-8
Ledipasvir (formerly GS-5885) is an experimental drug for the treatment of hepatitis C being developed by Gilead Sciences. It is currently in Phase III clinical trials. It is being studied in combination with other direct-acting antiviral agents that interfere with HCV replication.
Ledipasvir is an inhibitor of the hepatitis C virus HCV NS5A protein.
Ledipasvir is being tested in interferon-free regimens with other direct-acting antiviral agents for hepatitis C.
Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the HCV protease inhibitor sofosbuvir, ledipasvir…
View original post 121 more words